Literature DB >> 11713914

Serum level of macrophage migration inhibitory factor as a useful parameter of clinical course in patients with Wegener's granulomatosis and relapsing polychondritis.

R Ohwatari1, S Fukuda, K Iwabuchi, Y Inuyama, K Onoé, J Nishihira.   

Abstract

Novel biological activities of macrophage migration inhibitory factor (MIF) have been rediscovered. In addition, elevation of the serum MIF level has been reported in different types of disorders, including various inflammatory and autoimmune diseases. In the present study, serum MIF levels were analyzed in patients with Wegener's granulomatosis (WG) and relapsing polychondritis. It was shown that the serum MIF levels in these patients were significantly higher than those of normal healthy controls. In a WG patient, the MIF level showed a good correlation with clinical symptoms and C-ANCA titers. Thus, serum MIF levels will be a useful laboratory parameter for following the clinical course of WG patients and determining medical treatment. The immunopathologic roles of MIF in these diseases are discussed.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11713914     DOI: 10.1177/000348940111001108

Source DB:  PubMed          Journal:  Ann Otol Rhinol Laryngol        ISSN: 0003-4894            Impact factor:   1.547


  9 in total

Review 1.  Macrophage migration inhibitory factor (MIF): a promising biomarker.

Authors:  Gerrit Grieb; Melanie Merk; Jürgen Bernhagen; Richard Bucala
Journal:  Drug News Perspect       Date:  2010-05

2.  Relationship between serum levels of macrophage migration inhibitory factor and the activity of antineutrophil cytoplasmic antibody-associated vasculitides.

Authors:  Heidemarie Becker; Christian Maaser; Eva Mickholz; Anke Dyong; Wolfram Domschke; Markus Gaubitz
Journal:  Clin Rheumatol       Date:  2006-01-04       Impact factor: 2.980

3.  Role of Macrophage Migration Inhibitory Factor in Granulomatosis With Polyangiitis.

Authors:  Antoine G Sreih; Rana Ezzedine; Lin Leng; Juan Fan; Jie Yao; Duncan Reid; Marta Piecychna; Simon Carette; David Cuthbertson; Paul Dellaripa; Gary S Hoffman; Nader A Khalidi; Curry L Koening; Carol A Langford; Alfred Mahr; Carol A McAlear; Kathleen Maksimowicz-Mckinnon; Paul A Monach; Philip Seo; Ulrich Specks; E William St Clair; John H Stone; Steven R Ytterberg; Jeffrey Edberg; Peter A Merkel; Richard Bucala
Journal:  Arthritis Rheumatol       Date:  2018-10-22       Impact factor: 10.995

Review 4.  Relapsing polychondritis: a description of a case and review article.

Authors:  Amr Edrees
Journal:  Rheumatol Int       Date:  2011-01-19       Impact factor: 2.631

5.  Macrophage migration inhibitory factor (MIF) and thyroid hormone alterations in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV).

Authors:  Mårten Wendt; Ola Börjesson; Aune Avik; Johan Bratt; Björn Anderstam; Abdul R Qureshi; Edmund J Miller; Iva Gunnarsson; Annette Bruchfeld
Journal:  Mol Med       Date:  2013-05-20       Impact factor: 6.354

Review 6.  Efficacy of tocilizumab highlighted by FDG-PET/CT in a patient with relapsing polychondritis-associated aortitis.

Authors:  Ghassan Elourimi; Michael Soussan; Ursula Warzocha; Hélène Bugaud; Robin Dhôte; Sébastien Abad
Journal:  Rheumatol Int       Date:  2017-09-30       Impact factor: 2.631

7.  Macrophage migration inhibitory factor: a multifunctional cytokine in rheumatic diseases.

Authors:  Tsuyoshi Kasama; Kumiko Ohtsuka; Michihito Sato; Ryo Takahashi; Kuninobu Wakabayashi; Kazuo Kobayashi
Journal:  Arthritis       Date:  2010-12-26

8.  Increased serum levels of macrophage migration inhibitory factor (MIF) in patients with microscopic polyangiitis.

Authors:  Hirohito Kanemitsu; Mizuho Matsunawa; Kuninobu Wakabayashi; Michihito Sato; Ryo Takahashi; Tsuyoshi Odai; Takeo Isozaki; Nobuyuki Yajima; Yusuke Miwa; Tsuyoshi Kasama
Journal:  Open Access Rheumatol       Date:  2009-03-13

Review 9.  Macrophage migration inhibitory factor: a regulator of innate immunity.

Authors:  Thierry Calandra; Thierry Roger
Journal:  Nat Rev Immunol       Date:  2003-10       Impact factor: 53.106

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.